Hugely popular weight loss drugs known as GLP-1's are finally getting cheaper, well at least one is, and that's the case with ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...

Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...

在近期的美国股市中，礼来公司（Eli Lilly, LLY.US）以超2%的上涨，令市场投资者感到惊喜。周二，该公司股票交易价格达到902.26美元，尽管整体市场情绪受到一定压制，但礼来的这一表现显得尤为亮眼。这一异动的主要原因是礼来宣布将其畅销减肥药Zepbound的小瓶装价格下调，这一举措不仅笼络了消费者，也在市场上引发了广泛关注。

Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound. For many consumers, their insurance denies them ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound.

Eli Lilly announced a price reduction for its weight-loss drug Zepbound's vials by $50 or more, adapting to stiff competition ...

Eli Lilly and Company said Wednesday they plan to build new pharmaceutical manufacturing sites in the United States.

Eli Lilly (LLY) announced the launch of 7.5 mg and 10 mg Zepbound single-dose vials, available for $499 with the new Zepbound Self Pay Journey ...